97
Participants
Start Date
April 30, 2012
Primary Completion Date
April 30, 2014
Study Completion Date
April 30, 2014
SAR302503
"Pharmaceutical form:capsule~Route of administration: oral"
Investigational Site Number 040001, Vienna
Investigational Site Number 056002, Antwerp
Investigational Site Number 056003, Leuven
Investigational Site Number 040002, Salzburg
Investigational Site Number 840009, New York
Investigational Site Number 840018, New York
Investigational Site Number 250001, Marseille
Investigational Site Number 380001, Milan
Investigational Site Number 380003, Varese
Investigational Site Number 840017, Baltimore
Investigational Site Number 840013, Baltimore
Investigational Site Number 724003, Majadahonda
Investigational Site Number 840024, Charleston
Investigational Site Number 250003, Nîmes
Investigational Site Number 840005, Atlanta
Investigational Site Number 250004, Toulouse
Investigational Site Number 724002, Salamanca
Investigational Site Number 276006, Magdeburg
Investigational Site Number 840022, Cleveland
Investigational Site Number 840019, Middletown
Investigational Site Number 380004, Florence
Investigational Site Number 276003, Frankfurt am Main
Investigational Site Number 840014, Chicago
Investigational Site Number 276001, Mannheim
Investigational Site Number 250002, Paris
Investigational Site Number 250006, Paris
Investigational Site Number 840002, Houston
Investigational Site Number 840007, Phoenix
Investigational Site Number 276005, Ulm
Investigational Site Number 840003, San Francisco
Investigational Site Number 840004, San Francisco
Investigational Site Number 840001, Kansas City
Investigational Site Number 840010, Ann Arbor
Investigational Site Number 840015, Salt Lake City
Investigational Site Number 124001, Toronto
Investigational Site Number 276007, Leipzig
Investigational Site Number 380002, Roma
Investigational Site Number 528002, Amsterdam
Investigational Site Number 528003, Maastricht
Investigational Site Number 528001, Nijmegen
Investigational Site Number 724001, Barcelona
Investigational Site Number 826001, London
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY